Monoclonal Antibodies for Covid-19 in Patients with Solid Organ Transplant Recipients
1Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 2University of Arkansas for Medical Sciences, Little Rock, AR, 3Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, 4Transplant surgery, University of Arkansas for Medical Sciences, Little Rock, AR
Meeting: 2021 American Transplant Congress
Abstract number: LB 56
Keywords: Antibodies, COVID-19, N/A, Outpatients
Topic: Clinical Science » Infectious Disease » COVID-19
Session Information
Session Name: COVID-19
Session Type: Poster Abstract
Session Date & Time: None. Available on demand.
Location: Virtual
*Purpose: The FDA has issued Emergency Use Authorization (EUA) for monoclonal antibodies for the treatment of mild to moderate COVID-19 in patients at risk for progressing to severe disease. The authorized use includes treatment for patients with suppressed immune system (1,2). To our knowledge, there are no reports in the literature of Solid Organ Transplant Recipients receiving outpatient monoclonal antibodies for the treatment of mild to moderate COVID-19. We predict that SARS-CoV2 neutralizing antibodies infusion would help reduce hospital admissions and complications from SARS-CoV2 infection in this population.
*Methods: In this retrospective descriptive study, we identified patients with kidney and/or liver transplant who were diagnosed with SARS-CoV2 infection in the outpatient setting with mild symptoms at the time of diagnosis and agreed to receive one of the two products available. 17 total patients were identified and followed by clinic visits or phone calls. Follow-up assessment included complications from Bamlanivimab infusion, resolution or progression of symptoms, hospitalizations, and outcome. The assessment was conducted at time of presentation and at least three weeks later.
*Results: Out of the 17 patients, 14 had kidney transplant, 2 had liver and only one had both. Eleven patients received monoclonal antibodies within 10 days of symptom onset, 3 received it beyond 10 days of symptom onset and 3 patients had an unknown duration of symptoms before infusion. Three out of 17 patients (17%) experienced side effects after infusion including fever, myalgia, generalized weakness and pruritus. There were no serious adverse events. Four patients were hospitalized with a mean length of stay of 3.75 days (1-7 days). There were no ICU admissions. All 17 patients were alive at 3-week follow up.
*Conclusions: Infusion of monoclonal antibodies for the treatment of mild to moderate Covid-19 was a safe strategy for Solid Organ Transplant Recipients, reducing hospitalizations and mortality from SARS-CoV2 infections in such high-risk population.
To cite this abstract in AMA style:
Hasan L, Hardgrave H, Osborn T, Dare R, Burdine L, Giorgakis E, Rico J. Monoclonal Antibodies for Covid-19 in Patients with Solid Organ Transplant Recipients [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/monoclonal-antibodies-for-covid-19-in-patients-with-solid-organ-transplant-recipients/. Accessed May 11, 2025.« Back to 2021 American Transplant Congress